Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection

Rhea-AI Summary

Therapeutic Solutions International (TSOI) announced promising findings regarding its universal donor stem cell therapy, indicating potential applications for treating Chronic Obstructive Pulmonary Disease (COPD) and Acute Respiratory Distress Syndrome (ARDS). Research showed that CD103 expressing dendritic cells can transfer protection against these conditions to naïve mice. The company is advancing a Phase III clinical trial for JadiCells targeting ARDS from COVID-19 and is in discussions with the FDA regarding a new drug application for COPD treatment.

Positive

• New findings suggest protective effects of stem cells against COPD and ARDS.
• Data indicates that dendritic cells and exosomes could be key in therapeutic mechanisms.
• The company is progressing in Phase III clinical trials for COVID-19 associated ARDS.
• Application filed for Investigational New Drug regarding COPD treatment.

Negative

• None.

Clinical Stage Stem Cell Company Leverages Knowledge Gained from Cancer Dendritic Cell Therapy StemVacs to Open New Door for COPD and ARDS Research

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today new data suggesting that therapeutic effects of its universal donor stem cell product are mediated in part through CD103 expressing dendritic cells.

In a series of experiments, it was found that protection against both Chronic Obstructive Pulmonary Disease (COPD) and Acute Respiratory Distress Syndrome (ARDS) could be transferred to naïve mice by dendritic cells expressing the molecule CD103. Furthermore, exosomes, which are nanoparticles produced by cells, were capable of transferring protection to naïve mice.

“I am pleased to have worked with a team of opinion leaders that are at the cutting edge to have discovered this quite unexpected finding,” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “While the field of exosome therapeutics is growing exponentially, the use of dendritic cell exosomes for respiratory conditions is completely unheard of.”

Therapeutic Solutions International is currently running a Phase III clinical trial using JadiCells in the treatment of COVID-19 associated ARDS. Additionally, the Company has an Investigational New Drug Application IND# 28508 for treatment of COPD, for which the Company is still in discussions with the FDA.

“Dr. Veltmeyer has performed unparalleled work in advancing both clinical translation of the JadiCell, as well as leveraging scientific lessons learned from our cancer program to identify a new mechanism by which our cells exert this previously unknown therapeutic efficacy,” said Timothy Dixon, President, and CEO of the Company. “Having filed our patent today on this new finding, we anticipate potential development of adjuvant products around dendritic cell generated exosomes.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221003005541/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What did TSOI announce regarding COPD and ARDS research?

TSOI revealed new findings indicating that dendritic cells expressing CD103 can transfer protection against COPD and ARDS to naïve mice.

What is the status of TSOI's clinical trials?

TSOI is running a Phase III clinical trial for JadiCells in the treatment of COVID-19 associated ARDS.

Is TSOI pursuing treatment for COPD?

Yes, TSOI has an Investigational New Drug Application for the treatment of COPD and is in discussions with the FDA.

What does the recent research from TSOI suggest?

The research suggests that dendritic cell exosomes may play an unprecedented role in treating respiratory conditions.